David Harpole

3.3k total citations · 1 hit paper
16 papers, 1.9k citations indexed

About

David Harpole is a scholar working on Pulmonary and Respiratory Medicine, Surgery and Molecular Biology. According to data from OpenAlex, David Harpole has authored 16 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Pulmonary and Respiratory Medicine, 4 papers in Surgery and 4 papers in Molecular Biology. Recurrent topics in David Harpole's work include Lung Cancer Treatments and Mutations (5 papers), Pleural and Pulmonary Diseases (4 papers) and Occupational and environmental lung diseases (4 papers). David Harpole is often cited by papers focused on Lung Cancer Treatments and Mutations (5 papers), Pleural and Pulmonary Diseases (4 papers) and Occupational and environmental lung diseases (4 papers). David Harpole collaborates with scholars based in United States, Italy and United Kingdom. David Harpole's co-authors include Anil Potti, Andrea Bild, Holly K. Dressman, Andrew Berchuck, Johnathan M. Lancaster, Mike West, Guang Yao, M. Joshi, Jeffrey T. Chang and Quanli Wang and has published in prestigious journals such as Nature, Journal of Clinical Oncology and Annals of Oncology.

In The Last Decade

David Harpole

16 papers receiving 1.9k citations

Hit Papers

Oncogenic pathway signatures in human cancers as a guide ... 2005 2026 2012 2019 2005 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Oncogenic pathway signatures in human cancers as a guide to targeted therapies
    2005 1.5k citations Andrea Bild, Guang Yao et al. Nature profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
David Harpole United States 9 1.2k 586 528 498 167 16 1.9k
Evgeny Izumchenko United States 25 886 0.7× 611 1.0× 366 0.7× 509 1.0× 209 1.3× 74 1.8k
Ricardo Costa United States 22 848 0.7× 1.1k 1.9× 601 1.1× 540 1.1× 204 1.2× 82 2.2k
Pradip De United States 22 1.0k 0.9× 988 1.7× 438 0.8× 596 1.2× 82 0.5× 36 2.0k
Kenneth F. Grossmann United States 27 997 0.8× 1.2k 2.1× 517 1.0× 273 0.5× 178 1.1× 95 2.3k
Rosalie Fisher United Kingdom 15 788 0.7× 913 1.6× 424 0.8× 479 1.0× 71 0.4× 33 1.7k
Katherine E. Hutchinson United States 19 972 0.8× 920 1.6× 536 1.0× 595 1.2× 93 0.6× 48 1.8k
Stephen Leong United States 23 842 0.7× 1.1k 1.9× 471 0.9× 606 1.2× 350 2.1× 73 2.3k
Rebeca Sanz‐Pamplona Spain 25 885 0.7× 669 1.1× 370 0.7× 496 1.0× 120 0.7× 67 1.8k
Manickam Janakiraman United States 11 841 0.7× 672 1.1× 409 0.8× 414 0.8× 280 1.7× 19 1.7k
Eric C. Wooten United States 12 1.1k 0.9× 887 1.5× 398 0.8× 863 1.7× 114 0.7× 17 2.1k

Countries citing papers authored by David Harpole

Since Specialization
Citations

This map shows the geographic impact of David Harpole's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Harpole with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Harpole more than expected).

Fields of papers citing papers by David Harpole

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Harpole. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Harpole. The network helps show where David Harpole may publish in the future.

Co-authorship network of co-authors of David Harpole

This figure shows the co-authorship network connecting the top 25 collaborators of David Harpole. A scholar is included among the top collaborators of David Harpole based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Harpole. David Harpole is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
2.
Heymach, John V., David Harpole, Janis M. Taube, et al.. (2024). OA13.03 Perioperative Durvalumab for Resectable NSCLC (R-NSCLC): Updated Outcomes from the Phase 3 AEGEAN Trial. Journal of Thoracic Oncology. 19(10). S38–S39. 5 indexed citations
3.
He, Jianxing, Shugeng Gao, Martin Reck, et al.. (2023). OA12.06 Neoadjuvant Durvalumab + Chemotherapy Followed by Adjuvant Durvalumab in Resectable EGFR-mutated NSCLC (AEGEAN). Journal of Thoracic Oncology. 18(11). S72–S73. 7 indexed citations
4.
Waller, David, Isabelle Opitz, Raphael Bueno, et al.. (2020). Divided by an Ocean of Water but United in an Ocean of Uncertainty: A Transatlantic Review of Mesothelioma Surgery Guidelines. The Annals of Thoracic Surgery. 111(2). 386–389. 4 indexed citations
5.
Waller, David, Isabelle Opitz, Raphael Bueno, et al.. (2020). Divided by an ocean of water but united in an ocean of uncertainty: A transatlantic review of mesothelioma surgery guidelines. Journal of Thoracic and Cardiovascular Surgery. 161(6). 1922–1925. 2 indexed citations
6.
Waller, David, Isabelle Opitz, Raphael Bueno, et al.. (2020). Divided by an ocean of water but united in an ocean of uncertainty: a transatlantic review of mesothelioma surgery guidelines. European Journal of Cardio-Thoracic Surgery. 59(1). 8–11. 4 indexed citations
7.
Heymach, John V., Janis M. Taube, Tetsuya Mitsudomi, et al.. (2019). P1.18-02 The AEGEAN Phase 3 Trial of Neoadjuvant/Adjuvant Durvalumab in Patients with Resectable Stage II/III NSCLC. Journal of Thoracic Oncology. 14(10). S625–S626. 20 indexed citations
8.
9.
Dressman, Holly K., Andrea Bild, Jennifer Garst, David Harpole, & Anil Potti. (2006). Genomic signatures in non-small-cell lung cancer: Targeting the targeted therapies. Current Oncology Reports. 8(4). 252–257. 6 indexed citations
10.
Bild, Andrea, Guang Yao, Jeffrey T. Chang, et al.. (2005). Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature. 439(7074). 353–357. 1507 indexed citations breakdown →
11.
Bull, David A., David Harpole, Stephen Bailey, et al.. (2003). Transthoracic versus transhiatal esophagectomy: A prospective study of 945 patients. Journal of Thoracic and Cardiovascular Surgery. 125(5). 1114–1120. 116 indexed citations
12.
Harris, Lyndsay N., Vlayka Liotcheva, Gloria Broadwater, et al.. (2001). Comparison of Methods of Measuring HER-2 in Metastatic Breast Cancer Patients Treated With High-Dose Chemotherapy. Journal of Clinical Oncology. 19(6). 1698–1706. 89 indexed citations
13.
Salgia, Ravi, et al.. (2001). Role of serum tumor markers CA 125 and CEA in non-small cell lung cancer.. PubMed. 21(2B). 1241–6. 53 indexed citations
14.
Salgia, Ravi, et al.. (2000). Role of serum tumor markers CA125 and CEA in non-small cell lung cancer. Lung Cancer. 29(1). 191–191. 31 indexed citations
15.
Clary, Bryan M., et al.. (1997). Methemoglobinemia complicating topical anesthesia during bronchoscopic procedures. Journal of Thoracic and Cardiovascular Surgery. 114(2). 293–295. 27 indexed citations
16.
DeCamp, Malcolm M., Gary M. Strauss, D J Kwiatkowski, et al.. (1997). 731 Gender predicts survival in stage I NSCLC: Clinico-pathologic and molecular analysis of 250 patients. Lung Cancer. 18. 187–188. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Evgeny Izumchenko Breakdown of academic impact, for papers by Ricardo Costa Breakdown of academic impact, for papers by Pradip De Breakdown of academic impact, for papers by Kenneth F. Grossmann Breakdown of academic impact, for papers by Rosalie Fisher Breakdown of academic impact, for papers by Katherine E. Hutchinson Breakdown of academic impact, for papers by Stephen Leong Breakdown of academic impact, for papers by Rebeca Sanz‐Pamplona Breakdown of academic impact, for papers by Manickam Janakiraman Breakdown of academic impact, for papers by Eric C. Wooten
Rankless by CCL
2026